Evidence map›Paper›PMID 35127972›Full record

ArticleInternational journal of particle therapy2022

Comparative Effectiveness of Proton Therapy versus Photon Radiotherapy in Adolescents and Young Adults for Classical Hodgkin Lymphoma.

James E Bates, Stephanie Terezakis, Christopher G Morris, Avani D Rao, Shuchi Sehgal, Rahul Kumar, Raymond B Mailhot Vega, Nancy P Mendenhall, Bradford S Hoppe

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of particle therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

James E BatesDepartment of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Stephanie TerezakisDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, USA.
Christopher G MorrisDepartment of Radiation Oncology, University of Florida, Gainesville, FL, USA.
Avani D RaoDepartment of Radiation Oncology and Molecular Radiation Science, Johns Hopkins University, Baltimore, MD, USA.
Shuchi SehgalDepartment of Radiation Oncology and Molecular Radiation Science, Johns Hopkins University, Baltimore, MD, USA.
Rahul KumarSchool of Medical Sciences & Research, Sharda University, Greater Noida, India.
Raymond B Mailhot VegaUniversity of Florida Proton Therapy Institute, Jacksonville, FL, USA.
Nancy P MendenhallDepartment of Radiation Oncology, University of Florida, Gainesville, FL, USA.
Bradford S HoppeDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Johns Hopkins University · USUniversity of Florida Health · USEmory University · USMayo Clinic in Florida · USSharda University · INUniversity of Florida · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEarly stage (stages I-II) classical Hodgkin lymphoma (cHL) is a highly curable disease typically diagnosed in adolescents and young adults (AYAs). Proton therapy can also reduce the late toxicity burden in this population, but data on its comparative efficacy with photon radiotherapy in this population are sparse. We assessed outcomes in AYAs with cHL in a multi-institution retrospective review. MATERIALS AND

methodsWe identified 94 patients aged 15 to 40 years with stages I and II cHL treated with radiotherapy as part of their initial treatment between 2008 and 2017. We used Kaplan-Meier analyses and log-rank testing to evaluate survival differences between groups of patients.

resultsA total of 91 patients were included in the analysis. The 2-year progression-free survival (PFS) rate was 89%. Of the 12 patients who experienced progression after radiotherapy, 4 occurred out-of-field, 2 occurred in-field, and 6 experienced both in- and out-of-field progression. There was no significant difference in 2-year PFS among AYA patients by radiotherapy dose received (≥ 30 Gy, 91%; < 30 Gy, 86%;

conclusionOur cohort of AYA patients had comparable outcomes regardless of radiotherapy dose or modality used. For patients with significant risk of radiation-induced late effects, proton therapy is a reasonable treatment modality.

Indexed as

Hodgkin lymphomaoutcomespediatricsproton therapyradiation therapy

Identifiers

PMID35127972
PMCPMC8768899
OpenAlexW3178182820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.